The Expression Levels of Plasma Membrane Transporters in The Cholestatic Liver of Patients Undergoing Biliary Drainage and Their Association With The Impairment of Biliary Secretory Function

Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, wh...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of gastroenterology Vol. 96; no. 12; pp. 3368 - 3378
Main Authors Shoda, Junichi, Kano, Masahito, Oda, Koji, Kamiya, Junichi, Nimura, Yuji, Suzuki, Hiroshi, Sugiyama, Yuichi, Miyazaki, Hiroshi, Todoroki, Takeski, Stengelin, Siegfried, Kramer, Werner, Matsuzaki, Yasushi, Tanaka, Naomi
Format Journal Article
LanguageEnglish
Published Oxford . 01.12.2001
Blackwell Publishing
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subjects
Online AccessGet full text
ISSN0002-9270
1572-0241
DOI10.1111/j.1572-0241.2001.05339.x

Cover

Loading…
Abstract Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, which in turn depends on the expressions and functional activities of plasma membrane transporters in the liver. The aim of the present study was to determine the expression levels of these transporters in the cholestatic liver of patients undergoing PTBD. A total of 24 patients who had experienced obstructive cholestasis and had undergone preoperative PTBD were included in the study. Liver biopsy specimens were analyzed to determine the expression levels of the multidrug resistance-associated proteins (MRP) MRP2 and MRP3 and the canalicular bile salt export pump BSEP in the liver. The messenger RNA (mRNA) levels of MRP2, the canalicular bilirubin conjugate export pump, and bile salt export pump (BSEP) were unchanged in liver specimens from the 14 patients well drained by PTBD but were reduced in specimens from the 10 patients poorly drained, compared to the levels of control subjects. Immunostainings of MRP2 and BSEP outlined the canalicular membrane domain but seemed fuzzy to varying degrees in specimens obtained from cholestatic liver, especially in specimens from liver that had been poorly drained, in contrast to the linear and intense localization in the liver of control subjects, correlating with the impaired bilirubin conjugate and bile acid secretion. The mRNA of MRP3, functioning as an inducible export pump for bilirubin conjugate and bile acid, was expressed not only in the cholestatic liver but also in the liver of control subjects, and the mRNA level was increased in specimens from both the cholestatic liver that had been well drained and from the liver that had been poorly drained. Immunostaining of MRP3 was observed in the epithelia of intrahepatic bile ducts in the liver of both control subjects and cholestatic patients, and in the epithelia of proliferated bile ductules and the hepatocytes surrounding the portal tracts in the cholestatic liver. From the results of the present study, it is concluded that 1) the mRNA and immunohistochemical expression levels of MRP2 and BSEP may be altered in the cholestatic liver of patients undergoing PTBD; 2) both the decreased mRNA levels and the diminished canalicular membrane localization may be associated with the impairment of bile formation and secretion, i.e., the efficacy of PTBD; and 3) upregulated MRP3 in the cholangiocytes and hepatocytes may play a significant role in bile acid transport in the cholestatic hepatobiliary system.
AbstractList Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, which in turn depends on the expressions and functional activities of plasma membrane transporters in the liver. The aim of the present study was to determine the expression levels of these transporters in the cholestatic liver of patients undergoing PTBD. A total of 24 patients who had experienced obstructive cholestasis and had undergone preoperative PTBD were included in the study. Liver biopsy specimens were analyzed to determine the expression levels of the multidrug resistance-associated proteins (MRP) MRP2 and MRP3 and the canalicular bile salt export pump BSEP in the liver. The messenger RNA (mRNA) levels of MRP2, the canalicular bilirubin conjugate export pump, and bile salt export pump (BSEP) were unchanged in liver specimens from the 14 patients well drained by PTBD but were reduced in specimens from the 10 patients poorly drained, compared to the levels of control subjects. Immunostainings of MRP2 and BSEP outlined the canalicular membrane domain but seemed fuzzy to varying degrees in specimens obtained from cholestatic liver, especially in specimens from liver that had been poorly drained, in contrast to the linear and intense localization in the liver of control subjects, correlating with the impaired bilirubin conjugate and bile acid secretion. The mRNA of MRP3, functioning as an inducible export pump for bilirubin conjugate and bile acid, was expressed not only in the cholestatic liver but also in the liver of control subjects, and the mRNA level was increased in specimens from both the cholestatic liver that had been well drained and from the liver that had been poorly drained. Immunostaining of MRP3 was observed in the epithelia of intrahepatic bile ducts in the liver of both control subjects and cholestatic patients, and in the epithelia of proliferated bile ductules and the hepatocytes surrounding the portal tracts in the cholestatic liver. From the results of the present study, it is concluded that 1) the mRNA and immunohistochemical expression levels of MRP2 and BSEP may be altered in the cholestatic liver of patients undergoing PTBD; 2) both the decreased mRNA levels and the diminished canalicular membrane localization may be associated with the impairment of bile formation and secretion, i.e., the efficacy of PTBD; and 3) upregulated MRP3 in the cholangiocytes and hepatocytes may play a significant role in bile acid transport in the cholestatic hepatobiliary system.
Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, which in turn depends on the expressions and functional activities of plasma membrane transporters in the liver. The aim of the present study was to determine the expression levels of these transporters in the cholestatic liver of patients undergoing PTBD.OBJECTIVESPercutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, which in turn depends on the expressions and functional activities of plasma membrane transporters in the liver. The aim of the present study was to determine the expression levels of these transporters in the cholestatic liver of patients undergoing PTBD.A total of 24 patients who had experienced obstructive cholestasis and had undergone preoperative PTBD were included in the study. Liver biopsy specimens were analyzed to determine the expression levels of the multidrug resistance-associated proteins (MRP) MRP2 and MRP3 and the canalicular bile salt export pump BSEP in the liver.METHODSA total of 24 patients who had experienced obstructive cholestasis and had undergone preoperative PTBD were included in the study. Liver biopsy specimens were analyzed to determine the expression levels of the multidrug resistance-associated proteins (MRP) MRP2 and MRP3 and the canalicular bile salt export pump BSEP in the liver.The messenger RNA (mRNA) levels of MRP2, the canalicular bilirubin conjugate export pump, and bile salt export pump (BSEP) were unchanged in liver specimens from the 14 patients well drained by PTBD but were reduced in specimens from the 10 patients poorly drained, compared to the levels of control subjects. Immunostainings of MRP2 and BSEP outlined the canalicular membrane domain but seemed fuzzy to varying degrees in specimens obtained from cholestatic liver, especially in specimens from liver that had been poorly drained, in contrast to the linear and intense localization in the liver of control subjects, correlating with the impaired bilirubin conjugate and bile acid secretion. The mRNA of MRP3, functioning as an inducible export pump for bilirubin conjugate and bile acid, was expressed not only in the cholestatic liver but also in the liver of control subjects, and the mRNA level was increased in specimens from both the cholestatic liver that had been well drained and from the liver that had been poorly drained. Immunostaining of MRP3 was observed in the epithelia of intrahepatic bile ducts in the liver of both control subjects and cholestatic patients, and in the epithelia of proliferated bile ductules and the hepatocytes surrounding the portal tracts in the cholestatic liver.RESULTSThe messenger RNA (mRNA) levels of MRP2, the canalicular bilirubin conjugate export pump, and bile salt export pump (BSEP) were unchanged in liver specimens from the 14 patients well drained by PTBD but were reduced in specimens from the 10 patients poorly drained, compared to the levels of control subjects. Immunostainings of MRP2 and BSEP outlined the canalicular membrane domain but seemed fuzzy to varying degrees in specimens obtained from cholestatic liver, especially in specimens from liver that had been poorly drained, in contrast to the linear and intense localization in the liver of control subjects, correlating with the impaired bilirubin conjugate and bile acid secretion. The mRNA of MRP3, functioning as an inducible export pump for bilirubin conjugate and bile acid, was expressed not only in the cholestatic liver but also in the liver of control subjects, and the mRNA level was increased in specimens from both the cholestatic liver that had been well drained and from the liver that had been poorly drained. Immunostaining of MRP3 was observed in the epithelia of intrahepatic bile ducts in the liver of both control subjects and cholestatic patients, and in the epithelia of proliferated bile ductules and the hepatocytes surrounding the portal tracts in the cholestatic liver.From the results of the present study, it is concluded that 1) the mRNA and immunohistochemical expression levels of MRP2 and BSEP may be altered in the cholestatic liver of patients undergoing PTBD; 2) both the decreased mRNA levels and the diminished canalicular membrane localization may be associated with the impairment of bile formation and secretion, i.e., the efficacy of PTBD; and 3) upregulated MRP3 in the cholangiocytes and hepatocytes may play a significant role in bile acid transport in the cholestatic hepatobiliary system.CONCLUSIONSFrom the results of the present study, it is concluded that 1) the mRNA and immunohistochemical expression levels of MRP2 and BSEP may be altered in the cholestatic liver of patients undergoing PTBD; 2) both the decreased mRNA levels and the diminished canalicular membrane localization may be associated with the impairment of bile formation and secretion, i.e., the efficacy of PTBD; and 3) upregulated MRP3 in the cholangiocytes and hepatocytes may play a significant role in bile acid transport in the cholestatic hepatobiliary system.
OBJECTIVES:Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, which in turn depends on the expressions and functional activities of plasma membrane transporters in the liver. The aim of the present study was to determine the expression levels of these transporters in the cholestatic liver of patients undergoing PTBD.METHODS:A total of 24 patients who had experienced obstructive cholestasis and had undergone preoperative PTBD were included in the study. Liver biopsy specimens were analyzed to determine the expression levels of the multidrug resistance-associated proteins (MRP) MRP2 and MRP3 and the canalicular bile salt export pump BSEP in the liver.RESULTS:The messenger RNA (mRNA) levels of MRP2, the canalicular bilirubin conjugate export pump, and bile salt export pump (BSEP) were unchanged in liver specimens from the 14 patients well drained by PTBD but were reduced in specimens from the 10 patients poorly drained, compared to the levels of control subjects. Immunostainings of MRP2 and BSEP outlined the canalicular membrane domain but seemed fuzzy to varying degrees in specimens obtained from cholestatic liver, especially in specimens from liver that had been poorly drained, in contrast to the linear and intense localization in the liver of control subjects, correlating with the impaired bilirubin conjugate and bile acid secretion. The mRNA of MRP3, functioning as an inducible export pump for bilirubin conjugate and bile acid, was expressed not only in the cholestatic liver but also in the liver of control subjects, and the mRNA level was increased in specimens from both the cholestatic liver that had been well drained and from the liver that had been poorly drained. Immunostaining of MRP3 was observed in the epithelia of intrahepatic bile ducts in the liver of both control subjects and cholestatic patients, and in the epithelia of proliferated bile ductules and the hepatocytes surrounding the portal tracts in the cholestatic liver.CONCLUSIONS:From the results of the present study, it is concluded that 1) the mRNA and immunohistochemical expression levels of MRP2 and BSEP may be altered in the cholestatic liver of patients undergoing PTBD; 2) both the decreased mRNA levels and the diminished canalicular membrane localization may be associated with the impairment of bile formation and secretion, i.e., the efficacy of PTBD; and 3) upregulated MRP3 in the cholangiocytes and hepatocytes may play a significant role in bile acid transport in the cholestatic hepatobiliary system.
Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver injury through bile acid retention. The efficacy may be closely related to the capability of cholestatic liver to produce and secrete bile, which in turn depends on the expressions and functional activities of plasma membrane transporters in the liver. The aim of the present study was to determine the expression levels of these transporters in the cholestatic liver of patients undergoing PTBD. A total of 24 patients who had experienced obstructive cholestasis and had undergone preoperative PTBD were included in the study. Liver biopsy specimens were analyzed to determine the expression levels of the multidrug resistance-associated proteins (MRP) MRP2 and MRP3 and the canalicular bile salt export pump BSEP in the liver. The messenger RNA (mRNA) levels of MRP2, the canalicular bilirubin conjugate export pump, and bile salt export pump (BSEP) were unchanged in liver specimens from the 14 patients well drained by PTBD but were reduced in specimens from the 10 patients poorly drained, compared to the levels of control subjects. Immunostainings of MRP2 and BSEP outlined the canalicular membrane domain but seemed fuzzy to varying degrees in specimens obtained from cholestatic liver, especially in specimens from liver that had been poorly drained, in contrast to the linear and intense localization in the liver of control subjects, correlating with the impaired bilirubin conjugate and bile acid secretion. The mRNA of MRP3, functioning as an inducible export pump for bilirubin conjugate and bile acid, was expressed not only in the cholestatic liver but also in the liver of control subjects, and the mRNA level was increased in specimens from both the cholestatic liver that had been well drained and from the liver that had been poorly drained. Immunostaining of MRP3 was observed in the epithelia of intrahepatic bile ducts in the liver of both control subjects and cholestatic patients, and in the epithelia of proliferated bile ductules and the hepatocytes surrounding the portal tracts in the cholestatic liver. From the results of the present study, it is concluded that 1) the mRNA and immunohistochemical expression levels of MRP2 and BSEP may be altered in the cholestatic liver of patients undergoing PTBD; 2) both the decreased mRNA levels and the diminished canalicular membrane localization may be associated with the impairment of bile formation and secretion, i.e., the efficacy of PTBD; and 3) upregulated MRP3 in the cholangiocytes and hepatocytes may play a significant role in bile acid transport in the cholestatic hepatobiliary system.
Author Kramer, Werner
Todoroki, Takeski
Miyazaki, Hiroshi
Kano, Masahito
Suzuki, Hiroshi
Oda, Koji
Matsuzaki, Yasushi
Kamiya, Junichi
Sugiyama, Yuichi
Stengelin, Siegfried
Tanaka, Naomi
Shoda, Junichi
Nimura, Yuji
AuthorAffiliation Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan Department of Gastrointestinal Surgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan First Department of Surgery, Faculty of Medicine, Nagoya University School of Medicine, Nagoya, Japan Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan Department of Analytical Chemistry, Niigata College of Pharmacy, Niigata, Japan Research Metabolic Diseases, Hoechst Marion Roussel Deutschland, Frankfurt am Main, Germany
AuthorAffiliation_xml – name: Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan Department of Gastrointestinal Surgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan First Department of Surgery, Faculty of Medicine, Nagoya University School of Medicine, Nagoya, Japan Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan Department of Analytical Chemistry, Niigata College of Pharmacy, Niigata, Japan Research Metabolic Diseases, Hoechst Marion Roussel Deutschland, Frankfurt am Main, Germany
Author_xml – sequence: 1
  givenname: Junichi
  surname: Shoda
  fullname: Shoda, Junichi
  organization: Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan Department of Gastrointestinal Surgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan First Department of Surgery, Faculty of Medicine, Nagoya University School of Medicine, Nagoya, Japan Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan Department of Analytical Chemistry, Niigata College of Pharmacy, Niigata, Japan Research Metabolic Diseases, Hoechst Marion Roussel Deutschland, Frankfurt am Main, Germany
– sequence: 2
  givenname: Masahito
  surname: Kano
  fullname: Kano, Masahito
– sequence: 3
  givenname: Koji
  surname: Oda
  fullname: Oda, Koji
– sequence: 4
  givenname: Junichi
  surname: Kamiya
  fullname: Kamiya, Junichi
– sequence: 5
  givenname: Yuji
  surname: Nimura
  fullname: Nimura, Yuji
– sequence: 6
  givenname: Hiroshi
  surname: Suzuki
  fullname: Suzuki, Hiroshi
– sequence: 7
  givenname: Yuichi
  surname: Sugiyama
  fullname: Sugiyama, Yuichi
– sequence: 8
  givenname: Hiroshi
  surname: Miyazaki
  fullname: Miyazaki, Hiroshi
– sequence: 9
  givenname: Takeski
  surname: Todoroki
  fullname: Todoroki, Takeski
– sequence: 10
  givenname: Siegfried
  surname: Stengelin
  fullname: Stengelin, Siegfried
– sequence: 11
  givenname: Werner
  surname: Kramer
  fullname: Kramer, Werner
– sequence: 12
  givenname: Yasushi
  surname: Matsuzaki
  fullname: Matsuzaki, Yasushi
– sequence: 13
  givenname: Naomi
  surname: Tanaka
  fullname: Tanaka, Naomi
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13418129$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11774951$$D View this record in MEDLINE/PubMed
BookMark eNqFkt1u0zAAhSM0xLrBKyBLCO4S_BPHyQ3SKBtMKgKJTlxajuO0Lo7d2clWXo5nw267Ie0GXzix_J3j-OScZSfWWZVlAMECxfF-UyDKcA5xiQoMISogJaQpds-y2ePGSTaDEOK8wQyeZmchbCJIMaMvslOEGCsbimbZn-Vagcvd1qsQtLNgoe6UCcD14LsRYRDgqxpaL6wCyziHrfOj8gFoC5JwvnZGhVGMWoKFvlN-L4xLZccAbmyn_MppuwIftdHC_wafvNBWrBQQtksO2oOLEJzUURNP_6nH9d74etgK7Ydokxwf1D-U9Gp08e1qsjIpXmbPe2GCenV8nmc3V5fL-Zd88e3z9fxikUtSVizHoqZ1gzBqW6iqTrKuqVsKGa6orAgtG0JbhmNQvZAKdxXEUApZ9aRpBZWIkvPs3cF3693tFK_MBx2kMiYm46bAGSaMMlpG8M0TcOMmb-O3ccRq0jS0KVGkXh-pqR1Ux7deD_GC_OG_RODtERBBCtPH7KUO_zhSohrhJnIfDpz0LgSvei71uM9yjEkbjiBPheEbnnrBUy94KgzfF4bvokH9xODxjP9Ly4P03plUil9muleer5Uw45rDNEpS5kmD4gTzVEdG_gKf7NZX
CitedBy_id crossref_primary_10_1038_s41598_019_56790_4
crossref_primary_10_1016_j_heliyon_2023_e21009
crossref_primary_10_1016_S0169_409X_02_00075_3
crossref_primary_10_1111_j_1440_1746_2007_05109_x
crossref_primary_10_1371_journal_pone_0136215
crossref_primary_10_1002_hep_25591
crossref_primary_10_1002_hep_20899
crossref_primary_10_1007_s00424_006_0109_y
crossref_primary_10_1111_j_1440_1746_2003_03315_x
crossref_primary_10_1016_j_bbamcr_2006_04_014
crossref_primary_10_1016_j_jpba_2011_04_010
crossref_primary_10_1152_physrev_00027_2002
crossref_primary_10_1152_physrev_00037_2012
crossref_primary_10_1111_j_1872_034X_2008_00453_x
crossref_primary_10_1016_j_pharmthera_2010_03_005
crossref_primary_10_1016_j_jhep_2012_08_002
crossref_primary_10_1124_dmd_113_056358
crossref_primary_10_1016_S0168_8278_03_00410_0
crossref_primary_10_1097_MPG_0b013e3181596060
crossref_primary_10_1016_j_jhep_2009_05_012
crossref_primary_10_1152_ajpgi_00302_2006
crossref_primary_10_1124_dmd_121_000450
crossref_primary_10_1556_APhysiol_99_2012_1_7
crossref_primary_10_1021_mp060010s
crossref_primary_10_4132_KoreanJPathol_2009_43_1_48
crossref_primary_10_1074_jbc_M304011200
crossref_primary_10_1007_s00534_011_0396_3
crossref_primary_10_1097_00001574_200305000_00010
crossref_primary_10_1097_00008571_200404000_00001
crossref_primary_10_1016_j_pharmthera_2005_06_005
crossref_primary_10_1021_mp060011k
crossref_primary_10_1152_ajpgi_00499_2010
crossref_primary_10_1016_j_jhep_2011_11_021
crossref_primary_10_1016_S0168_8278_02_00234_9
crossref_primary_10_1124_jpet_105_090613
crossref_primary_10_1111_j_1476_5381_2008_00030_x
crossref_primary_10_1021_bi034462b
crossref_primary_10_1016_j_cld_2007_11_002
crossref_primary_10_1046_j_1365_2362_2003_01238_x
crossref_primary_10_3349_ymj_2006_47_6_817
crossref_primary_10_3748_wjg_14_6786
crossref_primary_10_1007_s00423_005_0564_5
crossref_primary_10_3748_wjg_v22_i1_72
crossref_primary_10_1007_s00204_013_1078_5
crossref_primary_10_1007_s00424_006_0152_8
crossref_primary_10_1515_BC_2004_029
crossref_primary_10_1089_ars_2021_0021
crossref_primary_10_1016_j_jprot_2013_08_019
crossref_primary_10_1007_s11605_014_2674_2
crossref_primary_10_1097_00001574_200205000_00005
crossref_primary_10_1111_j_1478_3231_2007_01506_x
crossref_primary_10_1369_jhc_5A6621_2005
crossref_primary_10_1042_CS20110184
crossref_primary_10_1016_S0168_8278_03_00096_5
crossref_primary_10_1203_PDR_0b013e318170a6b5
crossref_primary_10_1016_S1665_2681_19_32071_X
crossref_primary_10_1111_j_1478_3231_2008_01846_x
crossref_primary_10_2133_dmpk_25_190
crossref_primary_10_2174_0929867325666171205153204
crossref_primary_10_3390_antiox10030364
crossref_primary_10_1371_journal_pone_0022094
crossref_primary_10_1016_j_fct_2017_02_030
crossref_primary_10_1042_CS20070227
crossref_primary_10_1124_pr_55_3_1
crossref_primary_10_2174_0929867325666180221142315
crossref_primary_10_1002_hep_20003
crossref_primary_10_1016_j_bbadis_2010_12_021
crossref_primary_10_1517_17425255_4_5_545
crossref_primary_10_1016_j_bbadis_2006_11_005
crossref_primary_10_1016_j_cld_2012_12_001
crossref_primary_10_1016_j_cld_2007_11_010
crossref_primary_10_1124_jpet_102_035014
crossref_primary_10_3109_03602531003654915
crossref_primary_10_1007_s00210_006_0042_9
crossref_primary_10_1016_j_mam_2013_10_001
crossref_primary_10_1097_01_mcg_0000155551_37266_26
crossref_primary_10_1097_HC9_0000000000000612
crossref_primary_10_1371_journal_pone_0094675
Cites_doi 10.1016/S0016-5085(99)70138-1
10.1016/S0168-8278(96)80197-8
10.1002/hep.510310319
10.1006/abio.1976.9999
10.1172/JCI118535
10.1053/gast.1997.v112.pm9178697
10.1016/0378-4347(94)00107-3
10.1016/S0021-9258(19)75806-2
10.1073/pnas.96.12.6914
10.1093/clinchem/27.8.1352
10.1016/S0016-5085(97)70244-0
10.1074/jbc.274.21.15181
10.1074/jbc.273.16.10046
10.1016/S0014-5793(98)00899-0
10.1016/0378-4347(93)80078-I
10.1002/hep.510280625
10.1016/S0016-5085(97)70103-3
10.1002/hep.510290404
10.1002/hep.1840100408
10.1006/abio.1987.9999
10.1002/jso.2930080113
10.1097/00000658-197901000-00012
10.1002/hep.510290440
10.1172/JCI119816
10.1016/S0016-5085(00)70425-2
10.1016/S0016-5085(97)70238-5
10.1007/BF00437598
10.1016/0378-1119(88)90057-1
10.1016/0168-8278(88)80024-2
10.1007/BF01297095
10.1016/S0168-8278(96)80018-3
10.1002/hep.1840170518
10.1016/0002-9610(81)90296-8
10.1056/NEJM199810223391707
10.1074/jbc.275.4.2905
10.1016/0016-5085(86)90859-0
10.1073/pnas.87.1.152
10.1074/jbc.273.3.1684
10.1172/JCI116511
10.1136/gut.24.9.845
10.1016/0002-9610(81)90014-3
ContentType Journal Article
Copyright All Rights Reserved.
2002 INIST-CNRS
Copyright Nature Publishing Group Dec 2001
Copyright_xml – notice: All Rights Reserved.
– notice: 2002 INIST-CNRS
– notice: Copyright Nature Publishing Group Dec 2001
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
8BM
DOI 10.1111/j.1572-0241.2001.05339.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
ComDisDome
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
ComDisDome
MEDLINE - Academic
DatabaseTitleList
ComDisDome
ProQuest One Academic Middle East (New)
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1572-0241
EndPage 3378
ExternalDocumentID 4034166541
11774951
13418129
10_1111_j_1572_0241_2001_05339_x
00000434-200112000-00027
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
-Q-
.55
.GJ
0R~
123
1B1
1OC
23M
31~
36B
39C
3O-
4.4
4G.
53G
5RE
5VS
6J9
7X7
88E
8FI
8FJ
AAEDT
AAHPQ
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
AAYOK
ABAWZ
ABJNI
ABLJU
ABOCM
ABPXF
ABUWG
ABWVN
ACGFO
ACGFS
ACKTT
ACNWC
ACRPL
ADBBV
ADFRT
ADMUD
ADNKB
ADNMO
AEETU
AENEX
AEXYK
AFBPY
AFEBI
AFFNX
AFKRA
AFUWQ
AGAYW
AHMBA
AHSBF
AI.
AJAOE
AJRNO
AKRWK
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
C45
CAG
CCPQU
COF
CS3
EBS
EE.
EJD
EMB
EMOBN
F5P
FDB
FDQFY
FEDTE
FGOYB
FYUFA
HMCUK
HVGLF
HZ~
IHE
JSO
LH4
LW6
M1P
M41
N4W
NQ-
O9-
OVD
OVDNE
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
R2-
RLZ
RNT
RNTTT
ROL
RPZ
SSZ
SV3
TEORI
UDS
UKHRP
VH1
X7M
XPP
ZGI
ZZMQN
70F
8GM
AAAAV
AAGIX
AAIQE
AAJCS
AAMOA
AAQKA
AASCR
AASXQ
AAYXX
ABASU
ABDIG
ABVCZ
ABXYN
ABZZY
ACILI
ACLDA
ACOAL
ACXJB
ACXQS
ACZKN
ADGGA
ADHPY
AEBDS
AFBFQ
AFDTB
AFEXH
AFNMH
AGQPQ
AHOMT
AHQNM
AHQVU
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BYPQX
CITATION
DIWNM
EEVPB
ERAAH
FCALG
GNXGY
GQDEL
HLJTE
IKREB
IKYAY
IPNFZ
ODMTH
OPUJH
P0W
RIG
SEW
SJN
TSPGW
XIF
ZXP
IQODW
PJZUB
PPXIY
3V.
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
SNX
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
8BM
ID FETCH-LOGICAL-c3467-2a8589121bb0e6dc7d98b507265c6354935b72270face2d6020cac6f39ba5c153
IEDL.DBID 7X7
ISSN 0002-9270
IngestDate Mon Jul 21 10:43:57 EDT 2025
Fri Jul 25 04:29:28 EDT 2025
Wed Feb 19 02:03:11 EST 2025
Mon Jul 21 09:15:49 EDT 2025
Tue Jul 01 03:53:12 EDT 2025
Thu Apr 24 22:54:07 EDT 2025
Fri May 16 03:50:13 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Human
Immunohistochemistry
Plasma
Secretion
Instrumentation therapy
Hepatic disease
Biliary tract disease
Biological activity
Percutaneous route
Drainage
Pathology
Intrahepatic cholostasis
Association
Membrane transport
Digestive diseases
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3467-2a8589121bb0e6dc7d98b507265c6354935b72270face2d6020cac6f39ba5c153
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 11774951
PQID 1783995941
PQPubID 2041977
PageCount 11
ParticipantIDs proquest_miscellaneous_72375754
proquest_journals_1783995941
pubmed_primary_11774951
pascalfrancis_primary_13418129
crossref_citationtrail_10_1111_j_1572_0241_2001_05339_x
crossref_primary_10_1111_j_1572_0241_2001_05339_x
wolterskluwer_health_00000434-200112000-00027
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2001-December-01
PublicationDateYYYYMMDD 2001-12-01
PublicationDate_xml – month: 12
  year: 2001
  text: 2001-December-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: United States
– name: New York
PublicationTitle The American journal of gastroenterology
PublicationTitleAlternate Am J Gastroenterol
PublicationYear 2001
Publisher .
Blackwell Publishing
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Publisher_xml – name: .
– name: Blackwell Publishing
– name: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
References Evers R. (b31_639) 1996; 97
Vos T.A. (b46_654) 1998; 28
Paulusma C.C. (b13_621) 2000; 31
Michaesson M. (b23_631) 1961; 12
Aronsen K.F. (b4_612) 1961; 275
Craddock A.L. (b38_646) 1998; 274
Kubitz R. (b45_653) 1996; 116
Hansson J.A. (b5_613) 1979; 189
Shoda J. (b41_649) 1998; 29
b44_652
b33_641
Koyama K. (b1_609) 1981; 142
Bolder U. (b10_618) 1997; 112
Takada T. (b20_628) 1976; 8
Skol R.J. (b47_655) 1993; 17
b22_630
Konig J. (b49_657) 1999; 29
b32_640
Lazaridis K.N. (b19_627) 1997; 100
Aubel R.A.M.H. (b43_651) 1998; 53
Sehested M. (b34_642) 1981; 391
Ueda K. (b36_644) 1987; 262
Shoda J. (b25_633) 1997; 112
Trauner M. (b16_624) 1999; 30
Shoda J. (b40_648) 1997; 25
b39_647
b29_637
Mashige F. (b24_632) 1981; 27
Chojkier M. (b15_623) 1995; 13
Hirohashi T. (b17_625) 1998; 53
b18_626
Trauner M. (b11_619) 1997; 113
Pitt H.A. (b2_610) 1981; 141
Taniguchi K. (b30_638) 1996; 56
Bossard R. (b9_617) 1993; 91
b8_616
Novak D.A. (b28_636) 1989; 10
b7_615
Lee J.M. (b12_620) 2000; 118
b48_656
b37_645
Shimizu T. (b21_629) 1978; 19
b26_634
Yoon Y.B. (b52_660) 1986; 90
b51_659
Robert S.K. (b50_658) 1997; 112
Dixon J.M. (b3_611) 1983; 24
b14_622
George E. (b42_650) 1990; 87
Shoda J. (b27_635) 1993; 38
b35_643
Norlander A. (b6_614) 1982; 155
References_xml – volume: 116
  start-page: 401
  year: 1996
  ident: b45_653
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(99)70138-1
– ident: b39_647
  doi: 10.1016/S0168-8278(96)80197-8
– volume: 31
  start-page: 684
  year: 2000
  ident: b13_621
  publication-title: Hepatology
  doi: 10.1002/hep.510310319
– ident: b29_637
  doi: 10.1006/abio.1976.9999
– volume: 97
  start-page: 1211
  year: 1996
  ident: b31_639
  publication-title: J Clin Invest
  doi: 10.1172/JCI118535
– volume: 112
  start-page: 2036
  year: 1997
  ident: b25_633
  publication-title: Gastroenterology
  doi: 10.1053/gast.1997.v112.pm9178697
– volume: 155
  start-page: 161
  year: 1982
  ident: b6_614
  publication-title: Surg Gynecol Obstet
– ident: b22_630
  doi: 10.1016/0378-4347(94)00107-3
– volume: 262
  start-page: 505
  year: 1987
  ident: b36_644
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)75806-2
– volume: 25
  start-page: 18
  year: 1997
  ident: b40_648
  publication-title: Hepatology
– ident: b18_626
  doi: 10.1073/pnas.96.12.6914
– volume: 27
  start-page: 1352
  year: 1981
  ident: b24_632
  publication-title: Clin Chim Acta
  doi: 10.1093/clinchem/27.8.1352
– volume: 112
  start-page: 269
  year: 1997
  ident: b50_658
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(97)70244-0
– ident: b48_656
  doi: 10.1074/jbc.274.21.15181
– volume: 53
  start-page: 1062
  year: 1998
  ident: b43_651
  publication-title: Mol Pharmacol
– volume: 19
  start-page: 479
  year: 1978
  ident: b21_629
  publication-title: The rule of the serum bilirubin changes after the biliary decompression in patients with severe jaundice
– ident: b33_641
  doi: 10.1074/jbc.273.16.10046
– volume: 56
  start-page: 4124
  year: 1996
  ident: b30_638
  publication-title: Cancer Res
– ident: b32_640
  doi: 10.1016/S0014-5793(98)00899-0
– ident: b26_634
  doi: 10.1016/0378-4347(93)80078-I
– volume: 28
  start-page: 1637
  year: 1998
  ident: b46_654
  publication-title: Hepatology
  doi: 10.1002/hep.510280625
– volume: 275
  start-page: 1
  year: 1961
  ident: b4_612
  publication-title: Acta Chir Scand
– volume: 113
  start-page: 255
  year: 1997
  ident: b11_619
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(97)70103-3
– volume: 29
  start-page: 1156
  year: 1999
  ident: b49_657
  publication-title: Hepatology
  doi: 10.1002/hep.510290404
– volume: 10
  start-page: 447
  year: 1989
  ident: b28_636
  publication-title: Hepatology
  doi: 10.1002/hep.1840100408
– volume: 12
  start-page: 1
  year: 1961
  ident: b23_631
  publication-title: Scand J Clin Lab Invest
– ident: b35_643
  doi: 10.1006/abio.1987.9999
– volume: 8
  start-page: 83
  year: 1976
  ident: b20_628
  publication-title: J Surg Oncol
  doi: 10.1002/jso.2930080113
– volume: 13
  start-page: 37
  year: 1995
  ident: b15_623
  publication-title: Prog Liver Dis
– volume: 189
  start-page: 58
  year: 1979
  ident: b5_613
  publication-title: Ann Surg
  doi: 10.1097/00000658-197901000-00012
– volume: 53
  start-page: 1068
  year: 1998
  ident: b17_625
  publication-title: Mol Pharmacol
– volume: 29
  start-page: 1026
  year: 1998
  ident: b41_649
  publication-title: Hepatology
  doi: 10.1002/hep.510290440
– volume: 100
  start-page: 2714
  year: 1997
  ident: b19_627
  publication-title: J Clin Invest
  doi: 10.1172/JCI119816
– volume: 118
  start-page: 163
  year: 2000
  ident: b12_620
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(00)70425-2
– volume: 112
  start-page: 214
  year: 1997
  ident: b10_618
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(97)70238-5
– volume: 391
  start-page: 217
  year: 1981
  ident: b34_642
  publication-title: Virchows Arch
  doi: 10.1007/BF00437598
– ident: b37_645
  doi: 10.1016/0378-1119(88)90057-1
– ident: b7_615
  doi: 10.1016/0168-8278(88)80024-2
– volume: 38
  start-page: 2130
  year: 1993
  ident: b27_635
  publication-title: Dig Dig Sci
  doi: 10.1007/BF01297095
– ident: b14_622
  doi: 10.1016/S0168-8278(96)80018-3
– volume: 17
  start-page: 869
  year: 1993
  ident: b47_655
  publication-title: Hepatology
  doi: 10.1002/hep.1840170518
– volume: 142
  start-page: 293
  year: 1981
  ident: b1_609
  publication-title: Am J Surg
  doi: 10.1016/0002-9610(81)90296-8
– ident: b8_616
  doi: 10.1056/NEJM199810223391707
– ident: b51_659
  doi: 10.1074/jbc.275.4.2905
– volume: 90
  start-page: 837
  year: 1986
  ident: b52_660
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(86)90859-0
– volume: 274
  start-page: 157
  year: 1998
  ident: b38_646
  publication-title: Am J Physiol
– volume: 87
  start-page: 152
  year: 1990
  ident: b42_650
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.87.1.152
– volume: 30
  start-page: 467A
  year: 1999
  ident: b16_624
  publication-title: Hepatology
– ident: b44_652
  doi: 10.1074/jbc.273.3.1684
– volume: 91
  start-page: 2714
  year: 1993
  ident: b9_617
  publication-title: J Clin Invest
  doi: 10.1172/JCI116511
– volume: 24
  start-page: 845
  year: 1983
  ident: b3_611
  publication-title: Gut
  doi: 10.1136/gut.24.9.845
– volume: 141
  start-page: 66
  year: 1981
  ident: b2_610
  publication-title: Am J Surg
  doi: 10.1016/0002-9610(81)90014-3
SSID ssj0015275
Score 2.0329325
Snippet Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to lessen liver...
OBJECTIVES:Percutaneous transhepatic biliary drainage (PTBD) has been believed to reduce hyperbilirubinemia in patients with obstructive cholestasis and to...
SourceID proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3368
SubjectTerms Aged
ATP Binding Cassette Transporter, Sub-Family B - metabolism
Bile - chemistry
Bile - secretion
Bile Acids and Salts - metabolism
Bile Ducts - surgery
Biological and medical sciences
Blood - metabolism
Cholestasis, Intrahepatic - metabolism
Cholestasis, Intrahepatic - surgery
Digestive system
Drainage
Female
Gastroenterology
Humans
Immunoblotting
Immunohistochemistry
Investigative techniques, diagnostic techniques (general aspects)
Liver - metabolism
Male
Medical sciences
Membrane Transport Proteins - genetics
Membrane Transport Proteins - physiology
Middle Aged
Multidrug Resistance-Associated Proteins - metabolism
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
RNA, Messenger - metabolism
Title The Expression Levels of Plasma Membrane Transporters in The Cholestatic Liver of Patients Undergoing Biliary Drainage and Their Association With The Impairment of Biliary Secretory Function
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00000434-200112000-00027
https://www.ncbi.nlm.nih.gov/pubmed/11774951
https://www.proquest.com/docview/1783995941
https://www.proquest.com/docview/72375754
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEF-0BRFE_DbanvPga_TytZs8lSotRWgRsXBvy35Fjt4lZ3LF-s_5tzmz2dz1QIrPuVmOzGTmNzu_mWHsfSlskQlbxlpbEed5Uce0VyTmjrtcuVLXnox5fsHPLvMvs2IWLtz6QKscfaJ31LY1dEf-MREldWFWeXK0-hnT1iiqroYVGvfZPo0uo-RLzDYJF21sLUb4W6ViusvkKUQaY4TySWLygXpSq3EAUghPj1aqxzdVDysu_oVB8Te_Wipr91ee1X4rNp0-YY8DqITjwQqesnuuecYenIey-XP2B40B3E3gvDawIKZQD20NKwTPSwVLt8SsuXGw3sw673qYN4DwEMhBOmo8mhtYEI3DCw7zWHugJrTuR4sREIhnq7rfYGntBPopUI0FX4kAtbUCoKtffzB1aM47up6kE0fpnoAslf6BYi5JvGCXpyffP5_FYXFDbDJyvKkqaVlhmmg9ddwaYatSI_BMeWEQ4ORVVmiRokJqZVxqOUJWowyvs0qrwqAPfsn2mrZxrxmYqa6nRmRJVmISXxdKcFfZksaQOZ5YHjEx6kuaMNWclmss5K3sBjUtSdO0czORXtPyJmLJRnI1TPb4D5nJjklsBREMIFSqInYw2ogMzqCXW9ON2LvNY_yMqTaDum2veynSTCByziP2arCs7dEJInTEwRGLd0xNDo2yckjzspz8HYLnMCkgFW_u_itv2UNPp_PMnAO2t-6u3SHiq7We-I9owvY_nVx8_fYXf7AkDw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF5VRQKkCvGPobRzgKPBXv-sfUAIAVVKm55aKbdlvbtGEYmd2qnavhSPwLMxs7aTRkKIS8_JrCzN7Mw3O9_MMPYmEyaJhMn8ojDCj-Ok9GmviJ_a1MbKZkXpyJjjk3R0Fn-bJJMt9mvohSFa5eATnaM2taY38vehyKgLM4_Dj4tzn7ZGUXV1WKHRmcWRvb7ElK39cPgF9fuW84Ovp59Hfr9VwNcReQWuMtqkx8OiCGxqtDB5ViAq4mmiMfrGeZQUgnMRlEpbblLEU1rptIzyQiU6pC0R6PLvYOANiEIoJqsEjzbEJgPczvGETeZQIriPEdElpeE76oHNh4FLfTjcWagWNVN2KzX-hnnxP5c1ldHbn45FfyMWHjxkD3oQC586q3vEtmz1mN0d92X6J-w3Gh_Yq55jW8GMmEkt1CUsEKzPFcztHLP0ysJyNVu9aWFaAcJRIIdsqdFpqmFGtBEn2M1_bYGa3pofNUZcIF6vaq7B0JoL9IugKgOu8gFqbXVAT83uYOoInTb0HEonDtItAWeiGgDFeJJ4ys5uRaXP2HZVV_YFAx0UZaBFFEaZiHmZKJHa3GQ09symoUk9JgZ9Sd1PUadlHjN5I5tCTUvSNO34DKXTtLzyWLiSXHSTRP5DZm_DJNaCCD4QmuUe2x1sRPbOp5Xrq-Kx_dXP6DaoFoS6rS9aKXgkEKnHHnveWdb66BAzAsTdHvM3TE12jbmySyujmPwrgvV-MgEXL__9Kfvs3uh0fCyPD0-OXrH7jsrnWEG7bHvZXNjXiO2WxZ67UMC-3_YN_gOZg13E
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRaqQEOKN29LOAY6m8fqx9gEhRIlaSisOVMpt2ZeriMQOcaq2f40Dv42ZtZ00EkJcek5mZWle3-x-M8PY61zYNBY2D7W2IkyStAxpr0iYucwlyuW69GTM07Ps6Dz5PEpHG-xX3wtDtMo-JvpAbWtDd-QHkcipC7NIooOyo0V8PRy-n_0MaYMUvbT26zRaEzlxN1dYvjXvjg9R1284H3769vEo7DYMhCamCMFVTlv1eKT1wGXWCFvkGhESz1KDmTgp4lQLzsWgVMZxmyG2MspkZVxolZqINkZg-L8nYkyb6EtitCz2aFts2kPvAk9YZxGlgoeYHX2BGr2lftiiH77UpcYHM9Wglsp2vcbf8C_-56qmJ_Xmh2fU38qLw0fsYQdo4UNrgY_ZhquesK3T7sn-KfuNhgjuuuPbVjAhllIDdQkzBO5TBVM3xYq9crBYzlmfNzCuAKEpUHB21PQ0NjAhCokXbGfBNkANcPOLGrMvEMdXzW_A0soLjJGgKgv-FQTUygKBrp39wdQdOp7T1Sid2Es3BKKJdgCU70niGTu_E5U-Z5tVXbmXDMxAlwMj4ijORcLLVInMFTanEWgui2wWMNHrS5puojot9pjIW5UValqSpmnfZyS9puV1wKKl5KydKvIfMntrJrESRCCCMK0I2G5vI7ILRI1cuU3A9pc_YwihdyHUbX3ZSMFjgag9CdiL1rJWR0dYHSAGD1i4ZmqybdKVbYkZJxRrEbh3Uwq42P73p-yzLfRd-eX47GSH3fesPk8Q2mWbi_mle4Uwb6H3vD8B-37XDvwHGVJh-g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Expression+Levels+of+Plasma+Membrane+Transporters+in+The+Cholestatic+Liver+of+Patients+Undergoing+Biliary+Drainage+and+Their+Association+With+The+Impairment+of+Biliary+Secretory+Function&rft.jtitle=The+American+journal+of+gastroenterology&rft.au=Shoda%2C+Junichi&rft.au=Kano%2C+Masahito&rft.au=Oda%2C+Koji&rft.au=Kamiya%2C+Junichi&rft.date=2001-12-01&rft.pub=.&rft.issn=0002-9270&rft.volume=96&rft.issue=12&rft.spage=3368&rft.epage=3378&rft_id=info:doi/10.1111%2Fj.1572-0241.2001.05339.x&rft.externalDocID=00000434-200112000-00027
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9270&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9270&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9270&client=summon